Matthias Christgen

20PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Foetal development and medicinePredictive and prognostic markersCancer cell biologyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Apr 23, 2026
Reduced folate receptor alpha (FOLR1) protein expression in fallopian tubes from premenopausal women: implications for the FOLR1 CDx assay for mirvetuximab-soravtansine therapy.

|Nov 27, 2025
Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP®).

Alexander Scheiter, Sven Mattern, Verena Gassenmaier

|Nov 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Mar 03, 2025
Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

Max Ak Rätze, Lotte Nfl Enserink, Noboru Ishiyama

Pageof 4

Frequent Collaborators

7 joint publications

Stephan Bartels

6 joint publications

Monika K Graeser

6 joint publications

Oleg Gluz

6 joint publications

Sherko Kümmel